A Comparison of Visual Outcomes Between Patients Treated with Intravitreal Ranibizumab and Bevacizumab for Diabetic Macula Edema in A Real World Setting in Sub-Saharan Africa

Ophthalmology research and reports Pub Date : 2022-12-31 DOI:10.33425/2639-9482.1026

Oderinlo Olufemi, Hassan Adekunle, O. Idris, Odubela Tolulope, L. Oshunkoya

{"title":"A Comparison of Visual Outcomes Between Patients Treated with Intravitreal Ranibizumab and Bevacizumab for Diabetic Macula Edema in A Real World Setting in Sub-Saharan Africa","authors":"Oderinlo Olufemi, Hassan Adekunle, O. Idris, Odubela Tolulope, L. Oshunkoya","doi":"10.33425/2639-9482.1026","DOIUrl":null,"url":null,"abstract":"Aims and Objectives: To report a comparison of visual outcomes between patients treated with intravitreal ranibizumab and bevacizumab for diabetic macula oedema (DME) in a real-world setting in sub-Saharan Africa. Methods: A retrospective review of cases files of patients who were treated with either intravitreal ranibizumab or bevacizumab for diabetic macular edema in Eye Foundation Hospital Ikeja, Lagos, Nigeria between January 2018, and January 2019. Results: A total of 508 injections were received by 138 eyes of 115 patients within the study year and diabetic macular edema accounted for 36 eyes, (26.1%) of the total eyes that received either intravitreal Ranibizumab or Bevacizumab. There were 18 males (50%) and 18 (50%) females. Overall, the mean baseline pre injection BCVA was 0.32 ± 0.24 (range:0.05-1.0). One hundred and forty-three total injections of either Bevacizumab or Ranibizumab were received by the 36 eyes of DME participants. Fifteen eyes (41.7%) received Bevacizumab while 21 eyes (58.3%) received Ranibizumab injections. At 4 months a larger percentage of eyes (47.6%) that received Ranibizumab had better visual acuities compared to (13.3%) eyes that received Bevacizumab. At 6 months, more of the eyes that received Ranibizumab had better visual acuities (26.7%) compared to 23.8% that received Bevacizumab. At 9 months, more of the eyes that received Ranibizumab had better visual acuities (33.3%) compared to (19%) those that received Bevacizumab. However, these differences were not statistically significant. Compliance to treatment regime was poor, only 7 eyes of the 36 eyes (19.4%) were compliant, 5 eyes (33.3%) form Bevacizumab group and 2 eyes (9.5%) from the Ranibizumab group. Conclusion: Despite poor compliance, improvements in best corrected visual acuities was achieved and maintained with the use of either intravitreal bevacizumab or ranibizumab for diabetic macula edema in a real life setting in sub-Saharan Africa. Neither bevacizumab nor ranibizumab showed statistically significant superiority.","PeriodicalId":92830,"journal":{"name":"Ophthalmology research and reports","volume":"18 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ophthalmology research and reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33425/2639-9482.1026","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Aims and Objectives: To report a comparison of visual outcomes between patients treated with intravitreal ranibizumab and bevacizumab for diabetic macula oedema (DME) in a real-world setting in sub-Saharan Africa. Methods: A retrospective review of cases files of patients who were treated with either intravitreal ranibizumab or bevacizumab for diabetic macular edema in Eye Foundation Hospital Ikeja, Lagos, Nigeria between January 2018, and January 2019. Results: A total of 508 injections were received by 138 eyes of 115 patients within the study year and diabetic macular edema accounted for 36 eyes, (26.1%) of the total eyes that received either intravitreal Ranibizumab or Bevacizumab. There were 18 males (50%) and 18 (50%) females. Overall, the mean baseline pre injection BCVA was 0.32 ± 0.24 (range:0.05-1.0). One hundred and forty-three total injections of either Bevacizumab or Ranibizumab were received by the 36 eyes of DME participants. Fifteen eyes (41.7%) received Bevacizumab while 21 eyes (58.3%) received Ranibizumab injections. At 4 months a larger percentage of eyes (47.6%) that received Ranibizumab had better visual acuities compared to (13.3%) eyes that received Bevacizumab. At 6 months, more of the eyes that received Ranibizumab had better visual acuities (26.7%) compared to 23.8% that received Bevacizumab. At 9 months, more of the eyes that received Ranibizumab had better visual acuities (33.3%) compared to (19%) those that received Bevacizumab. However, these differences were not statistically significant. Compliance to treatment regime was poor, only 7 eyes of the 36 eyes (19.4%) were compliant, 5 eyes (33.3%) form Bevacizumab group and 2 eyes (9.5%) from the Ranibizumab group. Conclusion: Despite poor compliance, improvements in best corrected visual acuities was achieved and maintained with the use of either intravitreal bevacizumab or ranibizumab for diabetic macula edema in a real life setting in sub-Saharan Africa. Neither bevacizumab nor ranibizumab showed statistically significant superiority.

查看原文本刊更多论文

在撒哈拉以南非洲的真实世界环境中，玻璃体内注射雷尼单抗和贝伐单抗治疗糖尿病黄斑水肿患者的视力结果比较

目的和目的:报告在撒哈拉以南非洲的现实环境中，使用玻璃体内雷尼单抗和贝伐单抗治疗糖尿病黄斑水肿(DME)患者的视力结果的比较。方法:回顾性分析2018年1月至2019年1月在尼日利亚拉各斯Ikeja眼科基金会医院接受玻璃体内注射雷尼单抗或贝伐单抗治疗糖尿病黄斑水肿的病例档案。结果:研究年内115例患者138只眼共接受508次注射，糖尿病性黄斑水肿占36只眼，占玻璃体内注射雷尼单抗或贝伐单抗患者总数的26.1%。男性18只(50%)，女性18只(50%)。总体而言，平均基线注射前BCVA为0.32±0.24(范围:0.05-1.0)。DME参与者的36只眼睛共接受了143次贝伐单抗或雷尼单抗注射。15只眼(41.7%)接受贝伐单抗注射，21只眼(58.3%)接受雷尼单抗注射。在4个月时，接受雷尼单抗的眼睛视力较好(47.6%)，而接受贝伐单抗的眼睛视力较好(13.3%)。6个月时，接受雷尼单抗治疗的患者视力较好(26.7%)，而接受贝伐单抗治疗的患者视力较好(23.8%)。在9个月时，接受雷尼单抗的眼睛有更好的视力(33.3%)，而接受贝伐单抗的眼睛有更好的视力(19%)。然而，这些差异没有统计学意义。治疗方案的依从性较差，36只眼中只有7只眼(19.4%)符合治疗方案，贝伐单抗组5只眼(33.3%)，雷尼单抗组2只眼(9.5%)。结论:尽管依从性较差，但在撒哈拉以南非洲的现实生活中，使用玻璃体内贝伐单抗或雷尼单抗治疗糖尿病黄斑水肿，可实现并维持最佳矫正视力的改善。贝伐单抗和雷尼单抗均未显示统计学上的显著优势。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Ophthalmology research and reports

自引率

0.00%

发文量